BioCentury
ARTICLE | Clinical News

NKTT120 regulatory update

November 10, 2014 8:00 AM UTC

FDA granted Fast Track designation to NKTT120 from NKT to treat sickle cell disease. Next year, the company plans to start Phase IIb testing of the humanized mAb targeting invariant NK T (iNKT) cells ...